Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Renwick Goldberg (NPI 1679566178)

Field	Value
Entity Type	Individual
Organization	Renwick Goldberg
Address	8121 Rourk St
City	Myrtle Beach
State	SC
ZIP	29572
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 30, 2005

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider reports $2.2M in total Medicare revenue and has no Medicaid billing on file, so its public payer footprint is effectively single‑payer Medicare rather than a mixed Medicare/Medicaid practice. The absence of Medicaid activity should be considered when comparing payer mix or evaluating access to low‑income populations in state-level analyses.

Revenue is highly concentrated in a very small set of drugs and infusions: the precomputed top 3 Medicare codes account for 64.6% of this provider's total Medicare revenue, driven primarily by J9271 ($980.4K, 48.2%), J0897 ($190.4K, 9.4%), and J1437 ($144K, 7.1%). That concentration indicates the practice generates the majority of Medicare dollars from a few high‑value injectable treatments rather than from a broad mix of services.

The code mix and taxonomy (Hematology & Oncology Physician) point to an infusion‑centric oncology practice: J9271 (pembrolizumab) is the single largest revenue driver, and chemotherapy administration (96413, $46.5K) and other infusion/oncology drug codes appear in the top codes list. Combined with frequent E&M encounters, this pattern is consistent with a clinic that delivers office‑based immunotherapy and supportive injectable therapies.

Competitive standing on key drugs is mixed. J9271 ranks #282 of 1841 providers nationally (85th percentile; typical, unremarkable volume for this code), meaning the provider treats more pembrolizumab Medicare patients than most peers but is not an extreme national outlier; by contrast J1437 ranks #40 of 581 (93th percentile; notably above typical national volume for this code), signaling unusually high use of ferric derisomaltose relative to most providers. J0897 sits at #1139 of 10057 (89th percentile; typical, unremarkable volume), indicating solid but not dominant denosumab volume.

Office visit and clinical throughput are notable: E&M codes 99214 (1.3K claims, $119.3K, 5.9%) and 99213 (1.2K claims, $77.1K, 3.8%) are both listed and each is characterized as an extreme outlier at the 99th percentile, suggesting very high monthly visit volume per Medicare reporting compared with national peers. High volumes of basic labs and phlebotomy (e.g., 36415 $22.4K; 85025 $22.3K; 80076 $16.2K) with many lab codes at 97–99th percentiles further support a busy, vertically integrated outpatient clinic workflow that performs frequent in‑office testing.

The practice also bills for advanced imaging and radiotracer studies alongside infusions: PET/CT related codes such as 78815 ($73.3K, 3.6%) and A9552 ($23.8K, 1.2%) appear in the top codes, indicating either onsite imaging capability or a referral pattern that captures imaging‑associated billing. That combination of infusion drugs, imaging, and supportive labs suggests a comprehensive oncology ambulatory service line rather than a narrow procedural specialty.

Several ancillary therapies and supportive products appear meaningfully in the revenue mix — for example J1569 (immune globulin) at $106.1K (5.2%) and J0885 (epoetin alfa) at $57.1K (2.8%) — indicating the practice provides or bills for a range of non‑chemotherapy supportive infusions in addition to primary oncology therapies. These add‑on revenue streams diversify clinical services but remain subordinate to the dominant immunotherapy code.

Operational and business implications from the data: with nearly half of Medicare revenue coming from a single high‑cost biologic (J9271 $980.4K, 48.2%) and the top three codes comprising 64.6% of Medicare dollars, the provider's Medicare revenue is sensitive to utilization, reimbursement, or guideline changes affecting those agents. Combined with an NPI enumerated on 2005-08-30 (~21 years ago), the provider appears established in the market, operating a mid‑sized oncology practice that concentrates revenue in a small set of infusion therapies and high visit volumes rather than broad Medicaid or hospital‑based revenue streams.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

83 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,800	$40	$980.4K
J0897	Injection, denosumab, 1 mg	10,020	$20	$190.4K
J1437	Injection, ferric derisomaltose, 10 mg	9,000	$20	$144K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,280	$90	$119.3K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,120	$30	$106.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,220	$60	$77.1K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	100	$720	$73.3K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	9,520	$10	$57.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$100	$46.5K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	120	$200	$23.8K

Showing 1–10 of 83

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 83 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Renwick Goldberg — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

83 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	30	19,700	$40	$832K
J1569	12	20	3,860	$40	$161.4K
J1437	5	10	6,240	$20	$107.6K
J0897	34	250	2,400	$20	$91.2K
J3490	17	50	70	$510	$57.7K
78815	49	120	80	$220	$25.8K
99214	191	7,860	160	$80	$23.2K
96413	22	150	140	$90	$22.1K
J0885	4	20	2,220	$10	$21.3K
A9552	10	30	80	$200	$19.4K

Showing 1–10 of 83

Related Providers

Other providers that share a Tax Identification Number (TIN) with Renwick Goldberg, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jordan Henderson	SC	Hematology & Oncology Physician	$3.1M	$0
Dejuania Brown-rawls	SC	Hematology & Oncology Physician	$2.8M	$0
Patrick Francke	SC	Radiation Oncology Physician	$2.8M	$0
David Zaenger	SC	Radiation Oncology Physician	$2.3M	$0
Stephen Andrews	SC	Radiation Oncology Physician	$2M	$0
Nikhil Patel	SC	Hematology & Oncology Physician	$1.9M	$0
Emily Touloukian	SC	Hematology & Oncology Physician	$1.5M	$0
Vijay Paudel	SC	Hematology & Oncology Physician	$912.8K	$0
Tanya Bralley	SC	Medical Physician Assistant	$208.3K	$0
Angela Brinegar	SC	Adult Health Nurse Practitioner	$152.6K	$0

Nearby Providers

Other providers in the same ZIP code as Renwick Goldberg, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Acs Primary Care Physicians - Southeast PC	SC	Emergency Medicine Physician	$0	$81.7M
Grand Strand Pediatrics & Adolescent Medicine, P.A.	SC	Pediatric Adolescent Medicine Physician	$0	$28M
Grand Strand Regional Medical Center LLC	SC	General Acute Care Hospital	$0	$27.4M
Carolina Regional Surgery Center. Ltd	SC	Ambulatory Surgical Clinic/Center	$3M	$1.7M
Coastal Carolina Primary Care, LLC	SC	Endocrinology, Diabetes & Metabolism Physician	$0	$4M
Brandon Coakley	SC	MOHS-Micrographic Surgery Physician	$3.5M	$0
Parkway Surgery Center	SC	Ambulatory Surgical Clinic/Center	$3.5M	$0
David Lazar	SC	Rheumatology Physician	$2.7M	$0
Stephen Hammond	SC	Dermatopathology Physician	$2.3M	$0
David Chetrit	SC	Rheumatology Physician	$2.3M	$0

Renwick Goldberg — Billing Profile & Reimbursement Data

Sign up for Renwick Goldberg — Billing Profile & Reimbursement Data policy alerts

Renwick Goldberg — Billing Profile & Reimbursement Data

Sign up for Renwick Goldberg — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References